Clinical trial · Interventional
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Venous Thromboembolism Prophylaxis With Apixaban in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma Receiving Induction Therapy With an Immunomodulatory-based Regimen
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low recruitment
Summary
Brief summary (as posted)
Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for the prevention of thromboembolic events during induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma who receive bortezomib, thalidomide, and dexamethasone (VTD) during the induction phase of therapy prior to autologous stem cell transplantation (ASCT). The current study is designed to evaluate the efficacy and safety of apixaban during the induction period. Efficacy will be defined as a composite endpoint of acute symptomatic proximal and distal deep venous thrombosis, pulmonary embolism, VTE related deaths, and acute ischemic stroke.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apixaban 2.5 MG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Apixaban (single arm)
- interventionNames
- Drug: Apixaban 2.5 MG
Primary outcomes (35)
- measure
- Venous thromboembolism (VTE)- related death
- timeFrame
- Cycle 1 Day 1 (each cycle is 28 days. Treatment will finish on cycle 4 or 6. Treatment with Apixaban will continue until 14 days after cycle 4/6)
- description
- i.e. death for which VTE can not be excluded as a cause
- measure
- Venous thromboembolism (VTE)- related death
- timeFrame
- Cycle 2 Day 1 (each cycle is 28 days. Treatment will finish on cycle 4 or 6. Treatment with Apixaban will continue until 14 days after cycle 4/6)
- description
- i.e. death for which VTE can not be excluded as a cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent * Subjects must have documented newly diagnosed symptomatic multiple myeloma requiring front-line treatment. * Patients should be considered transplant-eligible * Subjects will receive front-line induction therapy with a triplet regimen consisting of bortezomib, thalidomide and dexamethasone (VTD). * To enter to the study at the same time of start anti myeloma induction therapy. * Ages eligible for study: 18 to 70 years. * Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2. Exclusion Criteria: * Patients with the diagnosis of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome or amyloidosis of light chain. * Patients with smouldering multiple myeloma or monoclonal gammopathy of undeterminated significance. * Patients considered non-transplant-eligible. * Grade ≥2 of peripheral neuropathy. * Prior history of documented any venous thromboembolism and arterial thrombosis event * Active or high risk of bleeding. * Need for on-going anticoagulant or antiplatelet treatment. * Contraindication of anticoagulant prophylaxis * Uncontrolled hypertension: systolic blood pressure \>200 mmHg and/or diastolic blood pressure \>100 mmHg. * HIV, HBV or HCV-positive active. * Expected survival \<6 months. * Weight \<40 Kg. * Low platelet count (\<50 x109/L). * ALT \>3x UNL, bilirubin \>2x ULN. * Creatinine clearance \<30 mL/min. * Women of childbearing potential who are unwilling to use an acceptable method of contraception. * Women of childbearing potential who are pregnant or breastfeeding. * Women with a positive pregnancy test on enrollment, prior to investigational product administration. * Administration of any investigational drug currently or within 30 days prior to planned enrollment into this study. * Subjects unwilling or unable to comply with study medication instructions or study procedures (e.g. bilateral lower extremity venous ultrasonography). * Known allergies to ingredients contained in apixaban. * Use of any contraindicated medications with apixaban (see section 5.4.1).
References
Publications (0)
Data not yet available